Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	13.02 $	+3.99%	60,903
26-06-16	12.52 $	+27.49%	123,584
26-06-15	9.820 $	-13.02%	91,566
26-06-12	11.29 $	-6.92%	58,741
26-06-11	12.13 $	-6.84%	78,469

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-17 EDT			5-day change	1st Jan Change
13.02 ^USD	+3.99%		-6.60%	-

06-15	Conexeu Sciences Inc. Announces Management and Committee Changes, Effective June 15, 2026	CI
06-08	Conexeu Sciences Inc. Reports Manufacturing Scale Up And Regulatory Progress For Lead CXU Wound Care Program	CI

06-15	Conexeu Sciences Inc. Announces Management and Committee Changes, Effective June 15, 2026	CI
06-08	Conexeu Sciences Inc. Reports Manufacturing Scale Up And Regulatory Progress For Lead CXU Wound Care Program	CI
05-28	Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T. Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine	CI
05-21	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to NASDAQ Composite Index	CI
05-19	Conexeu Sciences Inc. Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants	CI
05-14	Conexeu Sciences Inc Unveils Architecting Bioregeneration and Announces CXU Device Candidate	CI
04-01	Conexeu Sciences Inc. announced that it has received $1.815 million in funding	CI
03-26	Conexeu Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
03-24	Conexeu Sciences Inc. announced that it expects to receive $1.815 million in funding	CI
03-23	Conexeu Sciences Inc. announced that it has received $0.044698 million in funding	CI
03-15	Conexeu Sciences Inc. announced that it expects to receive $0.044698 million in funding	CI

06-16	Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower	AQ
06-15	Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing	AQ
06-09	A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus	AQ
06-08	Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program	AQ
06-03	Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026	AQ

1 day	+3.99%
1 week	-6.60%
Current month	+11.04%

Conexeu Sciences Inc. Stock

Stocks

CNXU

US20715F1003

Biotechnology & Medical Research

Chart: Conexeu Sciences Inc.

Latest news : Conexeu Sciences Inc.

Press Releases: Conexeu Sciences Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Conexeu Sciences Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	9.6	13.82
1 month	9.6	18.79
Current year	9.6	18.79
1 year	9.6	18.79
3 years	9.6	18.79
5 years	9.6	18.79
10 years	9.6	18.79

Manager	Title	Age	Since
Claudia Chavez-Munoz CTO	Chief Tech/Sci/R&D Officer	46	2023-10-15
Miles Harrison CEO	Chief Executive Officer	61	2025-10-22
David Bogart PRN	Corporate Officer/Principal	56	2026-06-14

Director	Title	Age	Since
David Bogart BRD	Director/Board Member	56	2023-11-12
Jeffrey Nathan Sharpe CHM	Chairman	54	2025-10-22
Miles Harrison BRD	Director/Board Member	61	2025-10-22

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-21	Jeffrey Nathan Sharpe	Fiscal year	Chairman	1,000,000	-
05-13	Z. Paul Lorenc	Free	Director	11,175	-
05-10	Z. Paul Lorenc	Other	Director	422,148	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONEXEU SCIENCES INC.	+3.99%	-6.60%	-	-	316M
LONZA GROUP AG	-0.22%	-0.40%	-13.00%	-13.09%	43.51B
REVOLUTION MEDICINES, INC.	+0.76%	+5.50%	+296.71%	+540.82%	33.29B
BEONE MEDICINES AG	-0.47%	-2.05%	-0.66%	+31.20%	29.34B
IQVIA HOLDINGS INC.	-4.74%	-8.37%	+7.17%	-20.99%	29.9B
CELLTRION, INC.	+0.06%	+2.71%	+13.31%	+21.11%	25.42B
ASCENDIS PHARMA A/S	-0.02%	+8.40%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-0.98%	-2.08%	+51.87%	+106.06%	13.18B
EUROFINS SCIENTIFIC SE	-0.29%	-3.76%	+2.12%	+1.69%	12.72B
IONIS PHARMACEUTICALS, INC.	+1.67%	-0.36%	+110.87%	+81.16%	12.08B
Average	-0.02%	-0.42%	+58.55%	+93.50%	21.41B
Weighted average by Cap.	-0.62%	+0.71%	+59.64%	+103.58%

	2024	2025
Net sales	-	-
Net income	-472K -410K -377K -355K -665K -44.6M -673K -4.48M -1.74M -21.91M -1.77M -1.73M -75.79M	-3.92M -3.41M -3.14M -2.95M -5.53M -371M -5.59M -37.26M -14.47M -182M -14.72M -14.41M -630M
Net Debt	-	-